Fattore Davide, Esposito Gianluca, Carangelo Ludovica, Luciano Maria Antonietta, Megna Matteo
Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples "Federico II", Naples, Italy.
Department of Neuroscience, Reproductive Sciences and Dentistry, "Federico II" University, Naples, Italy.
Case Rep Dermatol. 2024 Feb 21;16(1):42-46. doi: 10.1159/000535168. eCollection 2024 Jan-Dec.
Immune checkpoint inhibitors are new drugs approved for the treatment of many types of malignancies. Despite their wide use and unquestionable clinical benefits, these agents have also been associated with a unique spectrum of side effects known as immune-related adverse events. In this study, we report the first case of atezolizumab-induced pustular psoriasis and acrodermatitis.
A 61-year-old woman presented to our department with erythematous-desquamative and pustular lesions involving all hands and feet fingers, inguinal region, and trunk, associated to severe psoriatic onychodystrophy. She was affected by non-small-cell lung carcinoma from 12 years, and 7 months before admission, she started a treatment with atezolizumab.
Immune checkpoint inhibitors such as atezolizumab are linked to a plethora of adverse events. Identifying and treating certain adverse skin events, particularly in cancer patients, can be a challenge, leading oncologists to discontinue immunotherapy. Our case shows how it is necessary to have a shared therapeutic algorithm in order to manage serious skin reactions in cancer patients and avoid disruption of the oncotherapy.
免疫检查点抑制剂是被批准用于治疗多种恶性肿瘤的新药。尽管它们被广泛使用且具有毋庸置疑的临床益处，但这些药物也与一系列独特的副作用相关，即免疫相关不良事件。在本研究中，我们报告了首例阿替利珠单抗诱发的脓疱型银屑病和肢端皮炎病例。
一名61岁女性因双手和双脚手指、腹股沟区及躯干出现红斑脱屑性和脓疱性皮损，并伴有严重的银屑病甲营养不良前来我院就诊。她患非小细胞肺癌已12年，入院前7个月开始接受阿替利珠单抗治疗。
诸如阿替利珠单抗之类的免疫检查点抑制剂与大量不良事件有关。识别和治疗某些不良皮肤事件，尤其是在癌症患者中，可能是一项挑战，这会导致肿瘤学家停止免疫治疗。我们的病例表明，为了管理癌症患者的严重皮肤反应并避免肿瘤治疗中断，有必要制定一个共享的治疗方案。
